Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications announced the release of a groundbreaking product developed from Paige’s Pathology Foundation Model, Virchow. Built using one of the largest libraries of digitized images, utilizing unique computational resources provided by Microsoft Research, Paige has developed the first application that can detect cancer across more than 17 different tissue types including skin, lung, and the gastrointestinal tract, along with multiple rare tumor types and metastatic deposits.

Recommended AI News: WiMi Developed RPSSC Technology With Multiple Advantages in Hyperspectral Image Processing

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum”

Traditionally, development of pathology cancer detection AI applications required large datasets, one tissue type at a time, often taking months or years to build at clinical grade. By leveraging its unique Foundation Model, Paige has surpassed these limitations. With data derived from over 4 million digitized slides, Paige’s innovative approach removes the constraints of developing single tissue products, making it possible to efficiently create cancer detection AI applications across a multitude of tumor types, a first in AI-based cancer diagnosis.

“The early success of our Foundation Model has been possible due to the size, quality, and diversity of the datasets we used to build it,” said Siqi Liu, PhD, director of AI Science at Paige. “Paige has access to one of the largest and most highly regarded pathology datasets globally, which allows us to leverage cutting-edge deep-learning approaches to train systems to detect common, complex, and even very rare cancer entities. Paige’s development provides the pathology community with the most powerful tools for diagnosis, prognosis, biomarker development, and targeted selection of patients for precision therapy,” he continued.

The exceptional performance of Paige’s multi-cancer application across various tissue types is considered state-of-the art in cancer pathology AI. Paige is committed to ensuring its AI applications are clinical grade and will therefore continue to seek FDA regulatory oversight for products based on the Foundation Model technology.

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

“We see FDA clearance as being critical to ensure that regulatory and safety standards are being upheld in the application of AI in cancer diagnostics across tumor types,” said Andy Moye, CEO of Paige. “Paige remains at the forefront of innovation and regulatory milestones, and we expect this multi-tissue detection model to benefit patients, pathologists, and the broader medical community. Our commitment to excellence is exemplified by this groundbreaking achievement, marking a significant leap forward in cancer diagnostics.”

“Beyond its multi-tissue capabilities, the Foundation Model and the use of its embeddings can also be leveraged as a critical building block in a variety of upstream and downstream applications across the entire healthcare continuum,” said Razik Yousfi, Senior Vice President of Technology at Paige. “By combining the outputs of the Foundation Model with data types from other modalities, including genomics, radiology, and other health data, one can derive exponentially greater insights about the nature of cancer, its behavior, and response to specific treatments.”

Recommended AI News: OPENLANE Launches Visual Boost AI to Pinpoint Vehicle Damage

[To share your insights with us, please write to sghosh@martechseries.com]

The post Paige Unveils Game-Changing AI That Revolutionizes Cancer Detection Across Multiple Tissue Types appeared first on AiThority.

WellBe Senior Medical, an in-home value-based care provider to the Medicare Advantage population, announced an investment from CVS Health Ventures, the corporate venture capital arm of CVS Health. This strategic partnership and investment will help to accelerate WellBe’s national expansion. Today, WellBe operates in seven states, has over 107,000 Medicare Advantage members and over $2 billion in premium under management, and is the fastest-growing independent provider of value-based care in the home for Medicare Advantage.

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

The company’s rapid growth underscores the critical need for better solutions and investment in senior healthcare. “CVS Health Ventures is committed to helping provide seamless access to quality health care, especially for vulnerable populations like seniors,” says Vijay Patel, Managing Partner of CVS Health Ventures. “WellBe’s innovative approach to in-home medical care aligns with our vision of redefining the way health care is delivered in a multi-payor, patient-centric manner. Our collaboration with WellBe will support their mission to empower seniors to live healthier, happier lives in their homes.”

WellBe’s prescribing providers bring specialized geriatric care into the patient’s home. Many of the services available from a typical physician clinic are now delivered to the home, proactively managing care for the sickest and most complex Medicare Advantage patients. WellBe partners with Medicare Advantage health plans via global capitated risk arrangements to manage the ten to fifteen percent of members with very high and rising medical loss ratios. This allows WellBe to guarantee savings up front to the health plan and take on the risk of managing this costly population. By delivering proactive medical care at home, available to patients 24/7/365, WellBe’s best-in-class model helps avoid unnecessary hospitalizations, reducing total medical cost while improving overall patient satisfaction. Additionally, WellBe improves HEDIS ­­measures leading to an increase in Star Ratings from a low of 2.5 to a high of 4.5.

WellBe was cofounded by Chicago Pacific Founders (CPF) and provided the capital to grow WellBe to this point. CPF invests in founder-led healthcare services companies and helps drive healthcare services innovation forward. “WellBe has proven its ability to significantly improve the quality and health outcomes for the sickest and most frail in our communities,” said Mary Tolan, Founder and Managing Partner of CPF. “We are passionate about WellBe’s commitment to providing the level of care we want for our family members and loved ones. The patient outcomes speak profoundly of the company.”

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

“All of us have had an elderly friend or family member whose health increased in complexity with age, limiting every aspect of their life,” said Dr. Jeffrey Kang, Founder and CEO of WellBe Senior Medical. “This makes traditional office-based care inconvenient, unresponsive, and often unavailable when it’s needed. Instead of trying to bring these frail patients to the care, the solution is to brin­­g the care to the patient, in the comfort of their own home. We’ve found that WellBe can provide more than 90 percent of what occurs in a primary care doctor’s office conveniently at home. Access to WellBe’s in-home geriatric care should be available to everyone, which is why we’re passionate about partnering with payors nationwide, removing yet another barrier to care for patients. This collaboration with CVS Health Ventures fuels our mission to share our proven care model with more payors, more communities, and more patients.”

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post WellBe Senior Medical Secures Investment from CVS Health Ventures to Accelerate Nationwide Expansion appeared first on AiThority.

Medable Inc., the leading technology provider for modern clinical trials, announces new intelligent automation technology applied across its clinical trials platform to cut standard trial build timelines by at least half. Early application of the technology in electronic clinical outcomes assessment (eCOA) deployments – a major delay to study startup industry-wide – is groundbreaking. By automating laborious, manual tasks such as testing, Medable saves substantial time and removes eCOA from the critical path to trial go-live.

AiThority Interview Insights: AiThority Interview with Ramsey Masri, Chief Executive Officer at Ceres Imaging

Medable’s New Intelligent Automation Capabilities Cut Clinical Trial Technology Deployment Timelines by 50% #clinicaltrials #ai #clinicalresearch #studystartup #biosciences #healthcare #drugdevelopment

Medable’s new AI and automation capabilities catapult the company to the forefront of automating clinical trial operations and align with the industry’s perennial need to launch studies faster. Now, sponsors can eliminate common gridlocks caused by conversion, configuration, validation, and quality engineering. Top-10 global pharmaceutical companies are already benefiting from Medable’s novel technology, shaving weeks off build times.

As part of a broader roadmap incorporating AI and intelligent automation, Medable’s updated eCOA capabilities include an auto-configuration tool that produces standard configurations, such as schedules of assessments, anchor dates, and patient flags, in minutes. Medable’s auto-validate tool also eliminates weeks of tedious testing to automatically deliver a downloadable Configuration Validation Report (CVR) that validates the quality of study builds.

“We are reimagining the way clinical trials are deployed by eliminating many of the biggest process bottlenecks,” said Michelle Longmire, CEO and co-founder of Medable. “Starting with eCOA, we are accelerating clinical trials while helping to improve data quality – ultimately enabling our vision of a one-day study start-up to help deliver effective treatments and cures to patients faster. In 2024, expect to see more innovative technologies and new ways of delivering streamlined, patient-centric trials from Medable.”

Read More about AiThority Interview: AiThority Interview with Jim Kaskade, Chief Executive Officer at Conversica

Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A Tufts Center for the Study of Drug Development study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI respectively.

AiThority Interview Insights : AiThority Interview with Itamar Kandel, Chief Executive Officer at Vista.ai

 [To share your insights with us, please write to sghosh@martechseries.com] 

The post Medable’s Intelligent Automation Capabilities Reduce Clinical Trial Technology Deployment Timelines appeared first on AiThority.

The post Swoop Launches Predictive AI Targeting, the Next Generation of Healthcare Marketing appeared first on AiThority.

What AI can’t do is replace the natural ‘gut feel’ of a healthcare professional.

Smart Use of Artificial Intelligence in Health Care- How Robots are Helping Doctors?

With the help of AI, telemedicine and RPM may provide patients with up-to-the-minute health information. To guarantee ethical AI use, legislative frameworks, and ethical concerns have come to the fore. Instead of seeing AI as a replacement for human healthcare providers, the focus is on how AI systems may work in tandem with them. The picture highlights the revolutionary integration of AI into several aspects of healthcare, which holds great promise for better diagnoses, personalized treatments, and overall patient care.

By 2024, artificial intelligence is expected to make great strides in the medical field. Deep learning algorithms improve the accuracy of X-ray, MRI, and CT scan interpretation, which is useful in medical imaging and diagnostics. AI plays a crucial role in the drug discovery process by sifting through large datasets in search of promising compounds and automating development. Using a patient’s unique genetic and molecular profile, personalized medicine employs AI to create individualized treatment plans. Using natural language processing to glean insights from unstructured clinical data, predictive analytics helps with patient outcome prediction and at-risk population management.

The research examines six key areas where AI directly affects the patient and three sectors of the healthcare value chain that might gain from more scaling of AI. It also looks at specific instances of current AI solutions in healthcare.

The increase in investments isn’t surprising, as 90% of the healthcare leaders surveyed believe that AI initiatives are important for their organizations to remain competitive in the market. When asked about their organization’s approach to technology innovation, 80% self-reported that they are either edge experimenters (organizations that tend to be first adopters of new technology or first to try new approaches and test unknown use cases) or fast followers (organizations that typically are next in line to adopt after some experimentation).

Robots Cannot Substitute Doctors!

The post Can Robots Substitute Doctors? appeared first on AiThority.

How Can AI Fit Into the Field of Neonatology?

Preterm births account for about 10% of live births, and almost all preterm newborns have trouble feeding. The number of newborns in the United States who experience difficulty feeding is increasing, and it currently stands at over 2.8 million.

In neonatology, artificial intelligence is currently being tested for a variety of purposes, such as monitoring vital signs, diagnosing and prognosing neurological disorders, and predicting diseases such as respiratory distress syndrome, bronchopulmonary dysplasia, apnea of prematurity, retinopathy of prematurity, intestinal perforation, and jaundice.

A Review of NICU Data Quality

Think about a typical neonatal intensive care unit (NICU): the tempo of care is high, and practically all clinical decisions are made in real-time. The lack of high-quality data is already making those judgments difficult. Despite the wealth of clinical data stored in EHRs, the unstructured data that NICU teams require is frequently obscured, absent, or filled with errors in patient records.

A NICU nurse, for example, can probably tell if a dosage of medication has been inadvertently increased by zero based on a baby’s weight and can immediately account for the mistake because the human eye can fix many of these mistakes. That AI will act similarly is still a mystery to humans. Already, clinicians’ mistrust and the excessive amount of rework caused by poor data quality in NICUs are out of control.

It’s adding fuel to the fire of burnout among nurses who feel a moral imperative to verify every detail in a patient’s chart, even if they rarely have the opportunity to do so. Assuming the AI systems are indeed developed using pediatric data, NICUs are not in a position to responsibly rely on them for any part of patient care.

There is a dearth of pediatric data in current AI research, which causes researchers to draw incorrect conclusions about pediatric populations from adult datasets, as pointed out in a new framework of guidelines for the responsible use of pediatric data in AI studies. It is often believed that NICUs should immediately begin using AI to improve patient outcomes and decision-making. However, health systems would be better served by exercising prudence and bolstering the quality of their clinical data in NICUs. You get out of life what you put into it, as the adage goes.

The post NICUs And AI For Babies appeared first on AiThority.

Possessing human genome and microbiome data in all clinical stages
Becoming a global bio-healthcare big data platform company

Dx&Vx will develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS.

Dx&Vx recently announced on the 18th that it has signed a contract with LG CNS to jointly develop a bio-healthcare big data platform utilizing AI technology provided by LG CNS. This is the first case of LG CNS collaborating with a domestic pharma-bio company.

AiThority.com AI ML Trends: 10 AI In Manufacturing Trends To Look Out For In 2024

Dx&Vx is set to introduce an AI-driven digital medical and clinical data platform through its collaboration with LG CNS. LG CNS is a Google Cloud partner and key service provider. LG CNS will provide the AI and big data technologies needed to build the platform.

Through its cloud-based a precision medicine data platform, Dx&Vx has built a bio big data bridge system with Clidex CDx, a companion diagnostic (CDx) service, to provide a clinical decision support system (CDSS), Digital Therapeutics (DTx), and digital twin-based remote medicine, and will expand its service sales network to global markets such as new drug developers and pharmaceutical companies, medical institutions, and research institutes that need to provide precision medicine-based multi-omics analysis data and develop therapeutic drugs and related healthcare solutions.

Dx&Vx has more than 440,000 genomic analysis data, the largest in Korea. The data is clinical and genomic big data for clinical diagnosis and includes human genomic data and microbiome data in clinical stages, including embryonic stem cells for preimplantation genomic test, abortus tissues, cell free fetal DNA, amniocytes and chorionic villus sampling (CVS) tissues , blood and tissues of neonates, adults, and cancer cells.

In particular, it contains clinical data of various disease group as well as reference group, and is highly reliable and scalable for the discovery of disease subtype-specific biomarkers for various cancer, rare disease and infectious disease research, as well as for the development of therapeutics and identification of mechanisms of action according to genetic differences among ethnic groups, gender-omics and age differences.

AiThority.com News: Stereolabs and Syslogic Team Up to Advance Robotic Applications that Can Withstand Outdoor Condition

“Currently, we are implementing artificial intelligence (AI) algorithm in new drug development projects to increase the possibility of success in new drugs development, and we are expanding collaboration with domestic and foreign IT companies to expand related services. This joint development will be the starting point for Dx&Vx to grow into a global integrated biomedical big data-based bio-healthcare personalized precision medicine solution provider,” said an official from Dx&Vx.

Starting with the joint development, Dx&Vx plans to strengthen its collaboration with LG CNS to develop innovative bio-healthcare solutions based on its biomedical big data platform.

Meanwhile, global pharmaceutical giant GSK recently invested $300 million in genomic analysis company 23andME to develop new drugs using genomic information, and the Korea Bio Association predicts that the global genomic market will grow to $13.55 billion in 2024.

Top AI ML News: LILT Announces Enterprise AI Controls and In-App Multimodal Translation

[To share your insights with us, please write to sghosh@martechseries.com]

The post Dx&Vx co-develops a Bio-Healthcare Big Data Platform With LG CNS appeared first on AiThority.

Joint project with University of Skövde receives SEK 6 million Swedish governmental grant

Swedish tissue therapy company VERIGRAFT announced that along with the University of Skövde, SciCross and RISE, it is the joint recipient of a SEK 6 million grant from Sweden’s innovation agency Vinnova to develop an AI-based method to increase quality of graft manufacturing.

VERIGRAFT has developed a pioneering technique that uses autologous components from the recipient’s blood to create personalized tissue-engineered veins (P-TEV) that can be implanted without the need for immunosuppressive drugs. The Company is currently applying these grafts in the TECVI-1 first-in-man clinical trial in patients with chronic venous insufficiency (CVI).

Recommended AI News: CalmWave Launches on AWS Marketplace

In the new project due to run through to October 2026, researchers will gather data about genes, cells, proteins, and other factors from the recipient’s healthy vessels and various stages of the blood vessel production. In addition, data from both prior to implantation and one year after transplantation will be collected. The datasets will then be used to train an AI-model to understand patterns in the information and help predict manufacturing quality parameters. The goal is to use the method in the future during the manufacturing process and to accelerate product release for transplantation into a patient.

Recommended AI News: Vyopta Integrates Zoom QSS to Enhance Real-Time Monitoring and Analytics for Zoom Phone Users

“We are delighted to participate in this project since our long-term aim is develop personalized vein and artery grafts at scale and with highest quality,” says VERIGRAFT CEO Petter Björquist. “The data gathered in this project will also help us move towards 3D printing of graft scaffolds.”

“Our goal is to come up with improved AI tools that are digitalised and scalable for industrial production lines of ATMPs such as VERIGRAFTS’s tissue grafts. This will help patients gain access to new and promising treatments,” says Jane Synnergren, project leader and Professor in Bioinformatics, University of Skövde.

Recommended AI News: LocatorX Announces Intelligent IoT Platform Availability on Salesforce AppExchange

[To share your insights with us, please write to sghosh@martechseries.com]

The post VERIGRAFT to Use AI to Increase Quality of Vascular Grafts appeared first on AiThority.

Driven to transform and unify commercialisation services for pharmaceutical brands entering or expanding into Europe, EVERSANA, a leading provider of commercialisation services to the life sciences industry, has united seven leading organizations to form the Global Alliance for Pharma Solutions (GAPS).

Recommended AI News: Riding on the Generative AI Hype, CDP Needs a New Definition in 2024

GAPS harnesses a robust international network and unique technologies to meet the strategic demands of the pharmaceutical and healthcare sectors worldwide. Combined with EVERSANA, the alliance boasts over 8,400 professionals across more than 55 nations, including the following organizations:

• BI Pharma Laboratories, a nutraceutical company that provides quality services, logistical support and other infrastructure needs to drug manufacturers across Europe.
• Good Healthcare Group, a Berlin-based omnichannel provider to help brands connect with patients and physicians across Europe.
• Icon Group, LLC, a Spanish-based company that provides business process outsourcing, contract sales support, distribution services and technology consulting to the life sciences industry.
• Jakin, SA, a Switzerland-based company that provides contract sales outsourcing, product nursing and licensing services to the life sciences industry.
• MediPartner, a Belgium-based outsourced sales and marketing team in the pharmaceutical industry.
• MedHouse, a medical and regulatory consulting services, recruitment and project management team based in the Nordic Region.

Through the alliance, each partner will continue to offer their services independently but now have full access to EVERSANA’s proprietary technologies to help accelerate commercialisation efforts and provide more effective healthcare provider engagement strategies across the region.

announcement marks another important milestone in our collective effort to transform the life sciences sector across Europe and make a difference in the lives of patients,” said Jim Lang, CEO, EVERSANA.

Recommended AI News: Cloudflare’s R2 Is the Infrastructure Powering Leading AI Companies

Driven to transform and unify commercialisation services for pharmaceutical brands entering or expanding into Europe, EVERSANA, a leading provider of commercialisation services to the life sciences industry, has united seven leading organizations to form the Global Alliance for Pharma Solutions (GAPS).

GAPS harnesses a robust international network and unique technologies to meet the strategic demands of the pharmaceutical and healthcare sectors worldwide. Combined with EVERSANA, the alliance boasts over 8,400 professionals across more than 55 nations, including the following organizations:

• BI Pharma Laboratories, a nutraceutical company that provides quality services, logistical support and other infrastructure needs to drug manufacturers across Europe.
• Good Healthcare Group, a Berlin-based omnichannel provider to help brands connect with patients and physicians across Europe.
• Icon Group, LLC, a Spanish-based company that provides business process outsourcing, contract sales support, distribution services and technology consulting to the life sciences industry.
• Jakin, SA, a Switzerland-based company that provides contract sales outsourcing, product nursing and licensing services to the life sciences industry.
• MediPartner, a Belgium-based outsourced sales and marketing team in the pharmaceutical industry.
• MedHouse, a medical and regulatory consulting services, recruitment and project management team based in the Nordic Region.

EVERSANA is a leading independent provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 650 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world.

Read: Alteryx Launches New Alteryx AiDIN Innovations to Fuel Enterprise-wide Adoption of Generative AI

[To share your insights with us, please write to sghosh@martechseries.com]

The post European Life Science Companies Join Forces With EVERSANA for Global Pharma Solutions appeared first on AiThority.

 RxE2, the pioneer in pharmacy-led medical innovation, announces the launch of a groundbreaking technology platform that redefines the clinical trial landscape. RxE2 is the first technology company to seamlessly connect independent community pharmacies with the forefront of healthcare innovation, ushering in a new era of patient-centric and cost-effective clinical research.

Recommended AI News: OpenAI Is Working On GPT-5

At the core of RxE2’s innovation is a unique platform and marketplace for clinical trial services driven by the trusted relationship between pharmacists and patients. This revolutionary approach leverages the extensive independent community pharmacist insights about their patients, making clinical trials more accessible and significantly reducing timelines and costs. RxE2 is a Pharmacy Research Organization that collaborates with sponsors, CROs, and clinical sites to enhance the productivity and efficiency of clinical trials.

Mr. Gerald Finken, CEO of RxE2 expresses enthusiasm for this milestone, “As a pharmacist, I recognize the pivotal role community pharmacies play in patient care. RxE2 reached a significant milestone in integrating pharmacy practices into clinical trials. It’s not just about the data we have; it’s about knowing how to analyze it and putting the right tools in the hands of medication experts and other healthcare professionals to enhance clinical trial outcomes. We’re proud to lead this initiative and welcome the opportunity to integrate innovation at this crucial intersection of pharmacy and clinical research.”

The platform introduces artificial intelligence analytics with clinical trial-level rigor. Featuring real-time personalized insights and CFR Part 11 and HIPAA compliance, the platform translates data into opportunities and offers customer care insights during patient recruitment, drug dispensing, and counseling. RxE2 has access to millions of diverse patients, can process tens of millions of records in real-time, and perform thousands of medical queries to support and enhance clinical research.

Recommended AI News: New Cisco Technology Can Predict Network Issues Before They Happen

“Our platform is a game changer, seamlessly connecting clinical trial sponsors, community pharmacies, and patients, fostering a collaborative ecosystem that accelerates the pace of medical advancements,” says Doug Liberi, VP of Business Development & Sales at RxE2. “At the heart of our approach is a commitment to human-centric solutions empowering pharmacists to contribute to the future of medicine. Our platform equips them with the tools to play a pivotal role in shaping the narrative of clinical trials and patient well-being.”

RxE2 is not just a technology platform, but a commitment to enriching patient lives by offering them access to new care options. It empowers all stakeholders—sponsors/pharma companies, pharmacists, and patients—with innovation that transcends traditional boundaries in clinical research.

Recommended AI News: Getty Images Revolutionizes Visual Communications with VisualGPS Insights Launch

[To share your insights with us, please write to sghosh@martechseries.com]

The post RxE2 Revolutionizes Clinical Trials with Groundbreaking AI-led Technology Platform and Marketplace appeared first on AiThority.